| Michael Patrick Pruss, CRNA | |
|
1823 College Ave, Manhattan, KS 66502 | |
| (785) 776-3322 | |
| (785) 587-4277 |
| Full Name | Michael Patrick Pruss |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 24 Years |
| Location | 1823 College Ave, Manhattan, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316912165 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 55321 (Kansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Manhattan Surgical Hospital Llc | Manhattan, KS | Hospital |
| Ascension Via Christi Hospital Manhattain, Inc | Manhattan, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anesthesia Associates Llp | 4587631064 | 15 |
News Archive
BHR Pharma, LLC announced today the European Medicines Agency (EMA), responsible for evaluating medicines developed for use in the European Union, granted an orphan medicinal product designation for treating moderate and severe traumatic brain injury (TBI) to its proprietary intravenous progesterone infusion agent, BHR-100. The agent currently is being evaluated as a neuroprotective treatment for severe traumatic brain injury (TBI) in the global, Phase III SyNAPSe® clinical trial.
Visiting a crowded pediatric emergency department in Canada may increase the likelihood of being hospitalized but is not linked to delayed hospitalization or death in children, according to research in CMAJ.
Neurological symptoms have been widely reported in patients with COVID-19 and in those who have recovered from it. A new study led by Thomas Wisniewski of New York University Grossman School of Medicine, USA, finds that patients hospitalized with COVID-19 are more likely to have elevated biomarkers levels indicative of age-related neurodegeneration.
Preliminary research suggests that use of the anti-malarial drug hydroxychloroquine may help reduce the risk of the development of diabetes in patients with rheumatoid arthritis, according to a study in the July 11 issue of JAMA .
Bristol-Myers Squibb today announced 48-week data from an ongoing study (ETV-048) of chronic hepatitis B patients with decompensated cirrhosis, in which BARACLUDE demonstrated greater viral suppression compared to adefovir. The new BARACLUDE data were presented today at the 60th Annual Meeting of the American Association for the Study of Liver Diseases.
› Verified 3 days ago
| Entity Name | Anesthesia Associates Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043285935 PECOS PAC ID: 4587631064 Enrollment ID: O20040914000733 |
News Archive
BHR Pharma, LLC announced today the European Medicines Agency (EMA), responsible for evaluating medicines developed for use in the European Union, granted an orphan medicinal product designation for treating moderate and severe traumatic brain injury (TBI) to its proprietary intravenous progesterone infusion agent, BHR-100. The agent currently is being evaluated as a neuroprotective treatment for severe traumatic brain injury (TBI) in the global, Phase III SyNAPSe® clinical trial.
Visiting a crowded pediatric emergency department in Canada may increase the likelihood of being hospitalized but is not linked to delayed hospitalization or death in children, according to research in CMAJ.
Neurological symptoms have been widely reported in patients with COVID-19 and in those who have recovered from it. A new study led by Thomas Wisniewski of New York University Grossman School of Medicine, USA, finds that patients hospitalized with COVID-19 are more likely to have elevated biomarkers levels indicative of age-related neurodegeneration.
Preliminary research suggests that use of the anti-malarial drug hydroxychloroquine may help reduce the risk of the development of diabetes in patients with rheumatoid arthritis, according to a study in the July 11 issue of JAMA .
Bristol-Myers Squibb today announced 48-week data from an ongoing study (ETV-048) of chronic hepatitis B patients with decompensated cirrhosis, in which BARACLUDE demonstrated greater viral suppression compared to adefovir. The new BARACLUDE data were presented today at the 60th Annual Meeting of the American Association for the Study of Liver Diseases.
› Verified 3 days ago
| Entity Name | Rooks County Health Center |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1649278854 PECOS PAC ID: 8325959331 Enrollment ID: O20061104000195 |
News Archive
BHR Pharma, LLC announced today the European Medicines Agency (EMA), responsible for evaluating medicines developed for use in the European Union, granted an orphan medicinal product designation for treating moderate and severe traumatic brain injury (TBI) to its proprietary intravenous progesterone infusion agent, BHR-100. The agent currently is being evaluated as a neuroprotective treatment for severe traumatic brain injury (TBI) in the global, Phase III SyNAPSe® clinical trial.
Visiting a crowded pediatric emergency department in Canada may increase the likelihood of being hospitalized but is not linked to delayed hospitalization or death in children, according to research in CMAJ.
Neurological symptoms have been widely reported in patients with COVID-19 and in those who have recovered from it. A new study led by Thomas Wisniewski of New York University Grossman School of Medicine, USA, finds that patients hospitalized with COVID-19 are more likely to have elevated biomarkers levels indicative of age-related neurodegeneration.
Preliminary research suggests that use of the anti-malarial drug hydroxychloroquine may help reduce the risk of the development of diabetes in patients with rheumatoid arthritis, according to a study in the July 11 issue of JAMA .
Bristol-Myers Squibb today announced 48-week data from an ongoing study (ETV-048) of chronic hepatitis B patients with decompensated cirrhosis, in which BARACLUDE demonstrated greater viral suppression compared to adefovir. The new BARACLUDE data were presented today at the 60th Annual Meeting of the American Association for the Study of Liver Diseases.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Patrick Pruss, CRNA Po Box 516, Manhattan, KS 66505-0516 Ph: (800) 410-6030 | Michael Patrick Pruss, CRNA 1823 College Ave, Manhattan, KS 66502 Ph: (785) 776-3322 |
News Archive
BHR Pharma, LLC announced today the European Medicines Agency (EMA), responsible for evaluating medicines developed for use in the European Union, granted an orphan medicinal product designation for treating moderate and severe traumatic brain injury (TBI) to its proprietary intravenous progesterone infusion agent, BHR-100. The agent currently is being evaluated as a neuroprotective treatment for severe traumatic brain injury (TBI) in the global, Phase III SyNAPSe® clinical trial.
Visiting a crowded pediatric emergency department in Canada may increase the likelihood of being hospitalized but is not linked to delayed hospitalization or death in children, according to research in CMAJ.
Neurological symptoms have been widely reported in patients with COVID-19 and in those who have recovered from it. A new study led by Thomas Wisniewski of New York University Grossman School of Medicine, USA, finds that patients hospitalized with COVID-19 are more likely to have elevated biomarkers levels indicative of age-related neurodegeneration.
Preliminary research suggests that use of the anti-malarial drug hydroxychloroquine may help reduce the risk of the development of diabetes in patients with rheumatoid arthritis, according to a study in the July 11 issue of JAMA .
Bristol-Myers Squibb today announced 48-week data from an ongoing study (ETV-048) of chronic hepatitis B patients with decompensated cirrhosis, in which BARACLUDE demonstrated greater viral suppression compared to adefovir. The new BARACLUDE data were presented today at the 60th Annual Meeting of the American Association for the Study of Liver Diseases.
› Verified 3 days ago
Marc Christopher Heinitz, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1823 College Ave, Manhattan, KS 66502 Phone: 785-776-3322 Fax: 785-587-4277 | |
Albert John Giambrone, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1823 College Avenue, Manhattan, KS 66502 Phone: 785-776-3322 Fax: 785-587-4277 | |
Scott Alan Dobson, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1823 College Avenue, Manhattan, KS 66502 Phone: 785-776-3322 | |
Kevin M Carranza, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1823 College Ave, Manhattan, KS 66502 Phone: 785-776-3322 | |
Michael Ray Thomas, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 1823 College Ave, Manhattan, KS 66505 Phone: 785-776-3322 Fax: 785-587-4277 | |
Donald Paul Heon, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1823 College Ave, Manhattan, KS 66502 Phone: 785-776-3322 Fax: 785-587-4277 |